Keyphrases
Fluticasone Propionate
100%
Nocturnal Asthma
100%
Salmeterol xinafoate
100%
Bronchial Hyperresponsiveness
37%
Methacholine
37%
Forced Expiratory Volume in 1 Second (FEV1)
37%
Peak Expiratory Flow
37%
Circadian Variation
25%
Adenosine 5′-monophosphate
25%
Inflammation
12%
Clinical Outcomes
12%
Beneficial Effects
12%
Treatment Protocol
12%
Asthmatic
12%
β2-agonists
12%
Inhaled Corticosteroids
12%
Airway Obstruction
12%
Monotherapy
12%
Change Assessment
12%
Randomized Double-blind
12%
Airway Wall
12%
Best Medical Treatment
12%
Twice a Day
12%
Anti-inflammatory Capacity
12%
Circadian Fluctuation
12%
Immunology and Microbiology
Salmeterol
100%
Nocturnal Asthma
100%
Fluticasone Propionate
100%
Circadian Rhythm
42%
Forced Expiratory Volume
42%
Peak Expiratory Flow
42%
Asthma
14%
Agonist
14%
Isoetarine
14%
Fluticasone/Salmeterol
14%
Pharmacology, Toxicology and Pharmaceutical Science
Nocturnal Asthma
100%
Fluticasone Propionate
100%
Salmeterol Xinafoate
100%
Methacholine
37%
Adenosine Phosphate
25%
Inflammation
12%
Asthma
12%
Monotherapy
12%
Anti-Inflammatory Drug
12%
Beta 2 Adrenergic Receptor Stimulating Agent
12%
Airway Obstruction
12%
Neuroscience
Fluticasone Propionate
100%
Salmeterol
100%
Methacholine
42%
Peak Expiratory Flow
42%
Adenosine Monophosphate
28%
Anti-Inflammatory
14%
Agonist
14%
Isoetarine
14%
Fluticasone/Salmeterol
14%